The challenge of mild persistent asthma

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 5, 2005, Pages 517-527

  Irani, Anne Marie ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; NEDOCROMIL; PLACEBO; THEOPHYLLINE;

ASTHMA; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; MEDLINE; PERSISTENT INFECTION; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 19044394066     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61127-1     Document Type: Review

References (75)

1. Asthma Clinical Research Network. Improving Asthma Control Trial (IMPACT). Available at: http://www.acrn.org/impact.html. Accessed August 8, 2003.
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol. 2002;110:S141-S219.
3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop Report. Available at: www.ginasthma.com. Accessed October 6, 2003.
4. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute; July 1997. National Institutes of Health publication 98-4051.
5. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003;111:661-676.
6. Martinez FD. Development of wheezing disorders and asthma in preschool children. Pediatrics. 2002; 109:362-367.
7. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002;109:189-194.
8. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-1063.
9. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071-1076.
10. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003;349:1414-1422.
11. Szefler SJ, Boushey HA, Pearlman DS, et al. Time to onset of effect of fluticasone propionate in patients with asthma. J Allergy Clin Immunol. 1999;103:780-788.
12. Bleecker ER, Bresnahan BW, Hayden ML, Warren EH, Deniz Y. Asthma-related quality of life in patients with severe of difficult-to-treat asthma. Am J Respir Crit Care Med. 2003;167:A114.
13. Hayden ML, Dolan CM, Johnson CM, Morris SM, Bleecker ER. High level health care utilization in severe and difficult-to-treat asthma. J Allergy Clin Immunol. 2002;109:5293.
14. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-1397.
15. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol. 1992;13:95-100.
16. Jonasson G, Carlsen KH, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy. 2000;55:740-748.
17. Bukstein DA, Luskin AT, Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol. 2003;90:543-549.
18. Childhood Asthma Research and Education Network. Prevention of Early Asthma in Kids (PEAK). Available at: http://www.asthma-carenet.org/ clinicaltrials/peak.html. Accessed July 17, 2003.
19. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381.
20. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331:700-705.
21. Selroos O, Pietinalho A, Lofroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108:1228-1234.
22. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325:388-392.
23. Skoner DP. Balancing safety and efficacy in pediatric asthma management. Pediatrics. 2002;109:381-392.
24. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069.
25. Irani AM, Cruz-Rivera M, Fitzpatrick S, Hoag J, Smith JA. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol. 2002;88:306-312.
26. Eid N, Morton R, Olds B, Clark P, Sheikh S, Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics. 2002;109:217-221.
27. Ledford D, Apter A, Brenner AM, et al. Osteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol. 1998;102:353-362.
28. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-1383.
29. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002;87:457-461.
30. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients [published erratum appears in JAMA. 1998;280:1830]. JAMA. 1998;280:539-543.
31. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology. 2001;12:229-234.
32. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166:1563-1566.
33. Barnes N, Wei LX, Reiss TF, et al. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med. 2001;95:379-386.
34. van Adelsberg J, Montalvo J, Liu N, Knorr B, Wei LX, Reiss TF. Safety and tolerability of montelukast, a leukotriene receptor antagonist, in ≥6 to ≤31 month-old asthmatic patients: evaluation at 3 months [abstract]. Am J Respir Crit Care Med. 2003;167:A271.
35. van Adelsberg J, Wei LX, Knorr B, et al. Safety and tolerability of montelukast (sprinkles) in 6 to 24-month old asthmatic patients [abstract]. Am J Respir Crit Care Med. 2002;165:A744.
36. Knorr B, Matz J, Bernstein JA, et al; Pediatric Montelukast Study Group. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA. 1998;279:1181-1186.
37. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
38. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB; Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213-1220.
39. Pearlman DS, Lampl KL, Dowling PJ Jr, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther. 2000;22:732-747.
40. Singulair (montelukast). Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson; 2003:2086-2090.
41. Holgate ST. The anti-inflammatory role of cysteinyl leukotriene receptor antagonists in asthma. J Allergy Clin Immunol. 2003;111:S1-S70.
42. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM; The Zafirlukast Trialists Group. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther. 1997;19:675-690.
43. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol. 1998:102:935-942.
44. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al; Montelukast/ Beclomethasone Study Group. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med. 1999;130:487-495.
45. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002;110:847-854.
46. Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J. 2003;21:123-128.
47. Montelukast (Singulair) for allergic rhinitis. Med Lett Drugs Ther. 2003;45:21-22.
48. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immimol. 2001;108:S147-S334.
49. Price D. Tolerability of montelukast. Drugs. 2000;59:35-42; discussion 43-35.
50. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged 6 years. Clin Exp Allergy. 2001;31:77-87.
51. Dellaripa PF, Wechsler ME, Roth ME, Drazen J. Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents. Mayo Clin Proc. 2000;75:643-645.
52. Finkel TH, Hunter DJ, Paisley JE, Finkel RS, Larsen GL. Drug-induced lupus in a child after treatment with zafirlukast (Accolate). J Allergy Clin Immunol. 1999;103:533-534.
53. Actis GC, Morgando A, Lagget M, David E, Rizzetto M. Zafirlukast-related hepatitis: report of a further case. J Hepatol. 2001;35:539-541.
54. Moles JR, Primo J, Fernandez JM, Hinojosa JE. Acute hepatocellular injury associated with zafirlukast. J Hepatol. 2001;35:541-542.
55. Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med. 2000;133:964-968.
56. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279:455-457.
57. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf. 1999;21:241-251.
58. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117:708-713.
59. Wechsler M. Churg-Straus syndrome with montelukast. Thorax. 2001;56:417-418.
60. Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. Thorax. 1999;54:558-560.
61. Goransson LG, Omdal R. A severe systemic inflammatory reaction following therapy with montelukast (Singulair). Nephrol Dial Transplant. 2000;15:1054-1055.
62. Holloway J, Ferriss J, Groff J, Craig TJ, Klinek M, Klinik M. Churg-Strauss syndrome associated with zafirlukast [published erratum appears in J Am Osteopath Assoc. 1998;98:676]. J Am Osteopath Assoc. 1998;98:275-278.
63. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest. 1998;114:332-334.
64. Solans R, Bosch JA, Selva A, Orriols R, Vilardell M. Montelukast and Churg-Strauss syndrome. Thorax. 2002;57:183-185.
65. Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ. A drug interaction between zafirlukast and theophylline. Arch Intern Med. 1998;158:1713-1715.
66. Sekerel BE, Saraclar Y, Etikan I, Kalayci O. Comparison of two different dose regimens of nedocromil sodium with placebo in the management of childhood asthma. J Investig Allergol Clin Immunol. 1999;9:293-298.
67. Kannisto S, Voutilainen R, Remes K, Korppi M. Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. Pediatr Allergy Immunol. 2002;13:24-30.
68. 2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J. 1999;14:275-282.
69. Calhoun WJ, Hinton KL, Kratzenberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med. 2001;163:881-886.
70. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-930.
71. Pauwels RA, Lofdahl CG, Postma DS, et al; Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405-1411.
72. 2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol. 2000;29:221-234.
73. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001;138:694-698.
74. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319:87-90.
75. Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:49-54.